Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Blum and others began prescribing these lower doses to healthy patients in 2024
It also remains to be seen if this somewhat cheaper medicine will lead to more insurers covering the product.
The pipeline spans single receptor agonists, dual agonists incorporating GIP, glucagon, or amylin targets, triple agonists, and next-generation oral formulations
US$ 22.54
US$ 28.23
US$ 22.74
